University of Pennsylvania Researchers Pioneer Oral Diabetes Treatment Using Genetically Modified Lettuce

Scientists at the University of Pennsylvania have pioneered a groundbreaking technique for synthesizing GLP-1 receptor agonists, which are essential medications for managing diabetes and obesity. By utilizing genetically modified lettuce chloroplasts, the research team aims to revolutionize the delivery of these drugs. This innovative approach specifically addresses the two primary drawbacks of current blockbuster injectables like Ozempic and Wegovy: their exorbitant market price and the inconvenience of regular injections.

Under the leadership of Dr. Henry Daniell from the University of Pennsylvania School of Dental Medicine, the team successfully utilized lettuce to biosynthesize functional GLP-1 peptides, specifically exenatide and lixisenatide. A critical breakthrough in this method is the natural encapsulation of these peptides within the plant's cell walls. This biological shield protects the medication from the harsh environment of the human digestive system, including stomach acids and enzymes that typically degrade protein-based drugs.

This natural bioencapsulation effectively overcomes a long-standing hurdle in pharmaceutical science: the efficient oral delivery of peptide medications. By leveraging the internal biosynthetic machinery of plant chloroplasts, the researchers can produce active therapeutic substances with high efficiency. This method stands to significantly slash manufacturing expenses when compared to the complex and costly chemical synthesis processes used in traditional pharmaceutical manufacturing.

Dr. Daniell, a W.D. Miller Professor and a renowned pioneer in chloroplast genetic engineering, suggests that this strategy could democratize global healthcare access. He envisions a future where patients can receive life-saving treatment through what he metaphorically describes as a "lettuce leaf." Furthermore, the use of native GLP-1 peptides instead of synthetic versions may help minimize the severe gastrointestinal side effects that many patients report when using current commercial medications.

Currently, the high cost of injectable GLP-1 drugs like Ozempic and Wegovy—often ranging from $1,000 to $1,300 per month without insurance—places them out of reach for many individuals, particularly in low- and middle-income regions. The financial burden is exacerbated by the need for a continuous cold chain for storage and transport. In contrast, lettuce cells naturally perform the necessary post-translational modifications, eliminating several expensive chemical steps and potentially shortening the entire production cycle.

The Philadelphia-based research group is now focused on scaling up the cultivation of this transgenic lettuce in preparation for upcoming clinical trials. Dr. Daniell, who is a fellow of the American Association for the Advancement of Science (AAAS) and a foreign member of the National Academy of Sciences of Italy, brings decades of expertise in developing oral biopharmaceuticals. His previous successes include the development of plant-based vaccines and diabetes treatments using similar bioencapsulation techniques.

Findings published in the Plant Biotechnology Journal confirm that bacteria within the human gut are capable of breaking down the lettuce cell walls, thereby releasing the therapeutic peptides for absorption into the bloodstream. The reliability of this scaling process is supported by the Daniell laboratory's previous experience in producing kilograms of oral insulin. This proven track record provides a strong foundation for the commercial and clinical viability of this new oral diabetes treatment.